Piper Jaffray Resumes PDL BioPharma (PDLI) at Overweight, $4 PT
Tweet Send to a Friend
Piper Jaffray resumes coverage on PDL BioPharma (NASDAQ: PDLI) with a Overweight rating and a price target of $4.00.Analyst Charles ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
